Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2022

View Archived Issues

Medshine Discovery identifies new CREBBP and/or p300 inhibitors

Shionogi discovers 5-HT2A receptor antagonists and/or inverse agonists

New galectin-3 inhibitors synthesized at Galecto Biotech

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents G12C mutant GTPase KRAS inhibitors

IDP Discovery Pharma describes new VEGF inhibitors

M2-mAChRs as therapeutic targets for treating substance use disorders

Discovery of a new class of PDE4B inhibitors with activity in adjuvant-induced arthritis model

RAP-103 studies show potential of biphasic function opioid signaling modulators for use in analgesia

Step Pharma's CTPS1 inhibitor STP-938 cleared to enter clinic for T-cell and B-cell lymphomas

Tonix and KEMRI collaborate to advance TNX-801 as vaccine for monkeypox and smallpox

Neuron-like cells are glioblastoma's evil mastermind

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...